Long-term results from statin trials: Answers but more unresolved questions

European Heart Journal

Volumn 32, Issue 20, 2011, Pages 2479-2480

  De Backer, Guy G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; FOLLOW UP; MORTALITY; NOTE; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; PYRROLES;

EID: 80054737396     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr303     Document Type: Note

References (10)

1. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003;361:1149-1158. (Pubitemid 36398384)
2. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien E, Ostergren J. on behalf of the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes trial lipid lowering arm: Extended observations 2 year after trial closure. Eur Heart J 2008;29:499-508. (Pubitemid 351264177)
3. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, troedsson L, Kristianson J, berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K,Wedel H on behalf of the Scandinavian Simvastatin Survival Study Group. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000;86:257-262. (Pubitemid 30462217)
4. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002;359:1379-1387.
5. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 2005;5:2929-2936. (Pubitemid 43923954)
6. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J for the 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-777. (Pubitemid 39165096)
7. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, for the West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention study. N Engl J Med 2007;357: 1477-1486. (Pubitemid 47572633)
8. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, on behalf of the ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011;32: 2525-2532. First published on 28 August 2011. doi:10.1093/eurheartj/ehr333.
9. Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med 2010;104:1081-1091.
10. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: Cohort study. BMJ 2011;342:doi:10.1136/bmj. d1642.